Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure

Biochemical Pharmacology
Punniyakoti T VeeraveeduYoshifusa Aizawa

Abstract

Diuretics are frequently required to treat fluid retention in patients with chronic heart failure (CHF). Unfortunately, they can lead to a decline in renal function, electrolyte depletion, and neurohormonal activation. Arginine vasopressin (AVP) promotes renal water reabsorption via the V(2) receptor (V(2)R) and its levels are increased in CHF. This study was conducted to characterize the diuretic effect of tolvaptan, a non-peptide AVP V(2)R antagonist, and furosemide, a loop diuretic in a rat model of CHF after experimental autoimmune myocarditis. CHF was elicited in Lewis rats by immunization with porcine cardiac myosin, and 28 days after immunization rats were treated for 28 days with oral tolvaptan, and furosemide. CHF was characterized by left ventricular remodeling and impaired systolic and diastolic function. Tolvaptan produces a diuresis comparable to furosemide. Unlike tolvaptan, furosemide significantly increased urinary sodium and potassium excretion. Tolvaptan markedly elevated electrolyte-free water clearance (E-CH(2)O) or aquaresis to a positive value and increased urinary AVP excretion. In contrast to tolvaptan, furosemide elevated only electrolyte clearance (E-Cosm) but not E-CH(2)O. The differences in diuretic ...Continue Reading

References

Oct 1, 1975·Proceedings of the Society for Experimental Biology and Medicine·H E WilliamsonD E Van Orden
Jan 1, 1986·Journal of Cardiovascular Pharmacology·L B KinterF Stassen
May 1, 1967·The American Journal of Medicine·H D Lauson
Jul 1, 1995·Renal Physiology and Biochemistry·G RomanoE Bartoli
Sep 1, 1995·Acta Physiologica Scandinavica·O Tenstad, H E Williamson
Aug 6, 2000·British Journal of Pharmacology·K WatanabeY Aizawa
Apr 2, 2003·The New England Journal of Medicine·Bertram PittUNKNOWN Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators
Apr 5, 2003·American Journal of Physiology. Renal Physiology·Horng H ChenJohn C Burnett
Jul 10, 2003·American Heart Journal·Craig R LeeKirkwood F Adams
Jul 19, 2003·News in Physiological Sciences : an International Journal of Physiology Produced Jointly by the International Union of Physiological Sciences and the American Physiological Society·Volker Vallon
Aug 23, 2003·Journal of the American College of Cardiology·Michael DomanskiUNKNOWN Studies of Left Ventricular Dysfunction
Dec 4, 2003·Current Opinion in Pharmacology·Marc Thibonnier
Sep 29, 2005·American Journal of Physiology. Renal Physiology·Lisa C Costello-BoerrigterJohn C Burnett
Mar 27, 2007·JAMA : the Journal of the American Medical Association·Marvin A KonstamUNKNOWN Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
Mar 27, 2007·JAMA : the Journal of the American Medical Association·Mihai GheorghiadeUNKNOWN Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
Aug 28, 2007·Biochemical Pharmacology·Punniyakoti T VeeraveeduYoshifusa Aizawa

❮ Previous
Next ❯

Citations

Nov 29, 2011·Cardiovascular Drugs and Therapy·Toshiki MiyazakiHiroyuki Fujiki
May 25, 2010·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·A DavenportUNKNOWN Acute Dialysis Quality Initiative (ADQI) consensus group
Dec 19, 2008·Cardiology in Review·Gerard Oghlakian, Marc Klapholz
May 10, 2011·Heart Failure Reviews·Branko BraamCarlo Gaillard
Dec 11, 2014·Annual Review of Medicine·Vicente E Torres
Aug 17, 2010·Drug Discovery Today·Punniyakoti T VeeraveeduKenichi Watanabe
Nov 6, 2010·General and Comparative Endocrinology·Tatjana A KaravashkinaYuri V Natochin
Sep 6, 2013·Journal of Pharmacological Sciences·Takanori YamazakiYasukatsu Izumi
Jan 10, 2014·Journal of Pharmacological Sciences·Yasukatsu IzumiHiroshi Iwao
Nov 28, 2006·The American Journal of Cardiology·Saeed PayvarUNKNOWN Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators
Jul 12, 2016·International Heart Journal·Daisuke Nitta
Jul 10, 2003·American Heart Journal·Craig R LeeKirkwood F Adams
Sep 19, 2009·Heart Failure Reviews·Navneet S Rehsia, Naranjan S Dhalla
Feb 23, 2018·The Journal of International Medical Research·Lei Lei, Yuanjie Mao
Apr 16, 2010·Physiological Reviews·Hayo CastropCharlotte Wagner
Mar 16, 2011·Expert Opinion on Pharmacotherapy·Andrew AmbrosyMihai Gheorghiade
May 18, 2020·Nature Reviews. Cardiology·Eva M BoorsmaAdriaan A Voors
Apr 24, 2021·Journal of the American Society of Nephrology : JASN·Judith E HeidaArlene B Chapman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.